Age Related Macular Degeneration Drug Market Report

Global Age Related Macular Degeneration Drug Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 02, 2022
  • PAGES：137
  • REPORT CODE：GMM793494
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Age Related Macular Degeneration Drug market report explains the definition, types, applications, major countries, and major players of the Age Related Macular Degeneration Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Novartis

    • Regeneron Pharmaceuticals

    • Roche

    • Kanghong Pharma

    • Bayer HealthCare

    By Type:

    • Lucentis

    • Eylea

    • Avastin

    • Others

    By End-User:

    • Hospitals

    • Clinics

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Age Related Macular Degeneration Drug Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Age Related Macular Degeneration Drug Outlook to 2028- Original Forecasts

    • 2.2 Age Related Macular Degeneration Drug Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Age Related Macular Degeneration Drug Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Age Related Macular Degeneration Drug Market- Recent Developments

    • 6.1 Age Related Macular Degeneration Drug Market News and Developments

    • 6.2 Age Related Macular Degeneration Drug Market Deals Landscape

    7 Age Related Macular Degeneration Drug Raw Materials and Cost Structure Analysis

    • 7.1 Age Related Macular Degeneration Drug Key Raw Materials

    • 7.2 Age Related Macular Degeneration Drug Price Trend of Key Raw Materials

    • 7.3 Age Related Macular Degeneration Drug Key Suppliers of Raw Materials

    • 7.4 Age Related Macular Degeneration Drug Market Concentration Rate of Raw Materials

    • 7.5 Age Related Macular Degeneration Drug Cost Structure Analysis

      • 7.5.1 Age Related Macular Degeneration Drug Raw Materials Analysis

      • 7.5.2 Age Related Macular Degeneration Drug Labor Cost Analysis

      • 7.5.3 Age Related Macular Degeneration Drug Manufacturing Expenses Analysis

    8 Global Age Related Macular Degeneration Drug Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Age Related Macular Degeneration Drug Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Age Related Macular Degeneration Drug Export by Region (Top 10 Countries) (2017-2028)

    9 Global Age Related Macular Degeneration Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Age Related Macular Degeneration Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Lucentis Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Eylea Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Avastin Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Age Related Macular Degeneration Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Age Related Macular Degeneration Drug Market Analysis and Outlook till 2022

    • 10.1 Global Age Related Macular Degeneration Drug Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.2.2 Canada Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.2.3 Mexico Age Related Macular Degeneration Drug Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.2 UK Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.3 Spain Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.4 Belgium Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.5 France Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.6 Italy Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.7 Denmark Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.8 Finland Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.9 Norway Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.10 Sweden Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.11 Poland Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.12 Russia Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.3.13 Turkey Age Related Macular Degeneration Drug Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.4.2 Japan Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.4.3 India Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.4.4 South Korea Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.4.5 Pakistan Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.4.6 Bangladesh Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.4.7 Indonesia Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.4.8 Thailand Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.4.9 Singapore Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.4.10 Malaysia Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.4.11 Philippines Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.4.12 Vietnam Age Related Macular Degeneration Drug Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.5.2 Colombia Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.5.3 Chile Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.5.4 Argentina Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.5.5 Venezuela Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.5.6 Peru Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.5.7 Puerto Rico Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.5.8 Ecuador Age Related Macular Degeneration Drug Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.6.2 Kuwait Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.6.3 Oman Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.6.4 Qatar Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Age Related Macular Degeneration Drug Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.7.2 South Africa Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.7.3 Egypt Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.7.4 Algeria Age Related Macular Degeneration Drug Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Age Related Macular Degeneration Drug Consumption (2017-2022)

      • 10.8.2 New Zealand Age Related Macular Degeneration Drug Consumption (2017-2022)

    11 Global Age Related Macular Degeneration Drug Competitive Analysis

    • 11.1 Novartis

      • 11.1.1 Novartis Company Details

      • 11.1.2 Novartis Age Related Macular Degeneration Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Novartis Age Related Macular Degeneration Drug Main Business and Markets Served

      • 11.1.4 Novartis Age Related Macular Degeneration Drug Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Regeneron Pharmaceuticals

      • 11.2.1 Regeneron Pharmaceuticals Company Details

      • 11.2.2 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Main Business and Markets Served

      • 11.2.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Roche

      • 11.3.1 Roche Company Details

      • 11.3.2 Roche Age Related Macular Degeneration Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Roche Age Related Macular Degeneration Drug Main Business and Markets Served

      • 11.3.4 Roche Age Related Macular Degeneration Drug Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Kanghong Pharma

      • 11.4.1 Kanghong Pharma Company Details

      • 11.4.2 Kanghong Pharma Age Related Macular Degeneration Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Kanghong Pharma Age Related Macular Degeneration Drug Main Business and Markets Served

      • 11.4.4 Kanghong Pharma Age Related Macular Degeneration Drug Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Bayer HealthCare

      • 11.5.1 Bayer HealthCare Company Details

      • 11.5.2 Bayer HealthCare Age Related Macular Degeneration Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Bayer HealthCare Age Related Macular Degeneration Drug Main Business and Markets Served

      • 11.5.4 Bayer HealthCare Age Related Macular Degeneration Drug Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    12 Global Age Related Macular Degeneration Drug Market Outlook by Types and Applications to 2028

    • 12.1 Global Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Lucentis Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Eylea Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Avastin Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Age Related Macular Degeneration Drug Market Analysis and Outlook to 2028

    • 13.1 Global Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.2.2 Canada Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.2 UK Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.3 Spain Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.5 France Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.6 Italy Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.8 Finland Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.9 Norway Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.11 Poland Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.12 Russia Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.4.2 Japan Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.4.3 India Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.5.3 Chile Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.5.6 Peru Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.6.3 Oman Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Age Related Macular Degeneration Drug Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Age Related Macular Degeneration Drug

    • Figure of Age Related Macular Degeneration Drug Picture

    • Table Global Age Related Macular Degeneration Drug Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Age Related Macular Degeneration Drug Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Lucentis Consumption and Growth Rate (2017-2022)

    • Figure Global Eylea Consumption and Growth Rate (2017-2022)

    • Figure Global Avastin Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Age Related Macular Degeneration Drug Consumption by Country (2017-2022)

    • Table North America Age Related Macular Degeneration Drug Consumption by Country (2017-2022)

    • Figure United States Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Canada Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Mexico Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Age Related Macular Degeneration Drug Consumption by Country (2017-2022)

    • Figure Germany Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure UK Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Spain Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Belgium Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure France Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Italy Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Denmark Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Finland Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Norway Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Sweden Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Poland Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Russia Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Turkey Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Table APAC Age Related Macular Degeneration Drug Consumption by Country (2017-2022)

    • Figure China Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure India Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Thailand Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Singapore Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Philippines Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Table South America Age Related Macular Degeneration Drug Consumption by Country (2017-2022)

    • Figure Brazil Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Colombia Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Chile Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Argentina Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Peru Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Table GCC Age Related Macular Degeneration Drug Consumption by Country (2017-2022)

    • Figure Bahrain Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Oman Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Qatar Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Table Africa Age Related Macular Degeneration Drug Consumption by Country (2017-2022)

    • Figure Nigeria Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure South Africa Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Egypt Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure Algeria Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Table Oceania Age Related Macular Degeneration Drug Consumption by Country (2017-2022)

    • Figure Australia Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Age Related Macular Degeneration Drug Consumption and Growth Rate (2017-2022)

    • Table Novartis Company Details

    • Table Novartis Age Related Macular Degeneration Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Age Related Macular Degeneration Drug Main Business and Markets Served

    • Table Novartis Age Related Macular Degeneration Drug Product Portfolio

    • Table Regeneron Pharmaceuticals Company Details

    • Table Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Main Business and Markets Served

    • Table Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Portfolio

    • Table Roche Company Details

    • Table Roche Age Related Macular Degeneration Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Age Related Macular Degeneration Drug Main Business and Markets Served

    • Table Roche Age Related Macular Degeneration Drug Product Portfolio

    • Table Kanghong Pharma Company Details

    • Table Kanghong Pharma Age Related Macular Degeneration Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kanghong Pharma Age Related Macular Degeneration Drug Main Business and Markets Served

    • Table Kanghong Pharma Age Related Macular Degeneration Drug Product Portfolio

    • Table Bayer HealthCare Company Details

    • Table Bayer HealthCare Age Related Macular Degeneration Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer HealthCare Age Related Macular Degeneration Drug Main Business and Markets Served

    • Table Bayer HealthCare Age Related Macular Degeneration Drug Product Portfolio

    • Figure Global Lucentis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Eylea Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Avastin Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Age Related Macular Degeneration Drug Consumption Forecast by Country (2022-2028)

    • Table North America Age Related Macular Degeneration Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Age Related Macular Degeneration Drug Consumption Forecast by Country (2022-2028)

    • Figure Germany Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Age Related Macular Degeneration Drug Consumption Forecast by Country (2022-2028)

    • Figure China Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Age Related Macular Degeneration Drug Consumption Forecast by Country (2022-2028)

    • Figure Brazil Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Age Related Macular Degeneration Drug Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Age Related Macular Degeneration Drug Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Age Related Macular Degeneration Drug Consumption Forecast by Country (2022-2028)

    • Figure Australia Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Age Related Macular Degeneration Drug Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US